Clinical trials
Completed Cholangiocarcinoma trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| First People's Hospital of Hangzhou | 4 |
| Bing Hu | 1 |
| Campus Bio-Medico University | 1 |
| China Medical University, China | 1 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Hackensack Meridian Health | 1 |
| Hepatopancreatobiliary Surgery Institute of Gansu Province | 1 |
| Huazhong University of Science and Technology | 1 |
| Humanitas Clinical and Research Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholangiocarcinoma | 29 |
| Pancreatic Neoplasms | 8 |
| Carcinoma, Hepatocellular | 5 |
| Liver Neoplasms | 4 |
| Biliary Tract Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Gallbladder Neoplasms | 2 |
| Stomach Neoplasms | 2 |
| Cholecystitis, Acute | 1 |
| Choledocholithiasis | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.